Literature DB >> 10492160

Radiation myelopathy: new perspective on an old problem.

C Nieder1, F Ataman, R E Price, K K Ang.   

Abstract

This article discusses recent advances in basic research that alter the view of the pathogenesis of radiation myelopathy and summarizes the available data from developmental neurobiology and preclinical studies on demyelinating diseases. These studies have produced interesting insights into oligodendrocyte development, intercellular signaling pathways, and myelination processes. Current findings suggest that administration of cytokines as platelet-derived growth factor and basic fibroblast growth factor could increase proliferation of oligodendrocyte progenitors, enhance their differentiation, up-regulate synthesis of myelin constituents, and promote myelin regeneration in the adult central nervous system (CNS). Other compounds might also be able to modulate the progression of pathogenic processes that lead to myelopathy. In addition, several possible biological prevention or treatment strategies, for example stimulation of endogenous cellular regeneration and glial cell transplantation, are discussed. Rationally designed animal experiments pursuing such strategies could further elucidate the pathogenesis of radiation-induced CNS damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492160     DOI: 10.1002/(SICI)1520-6823(1999)7:4<193::AID-ROI1>3.0.CO;2-S

Source DB:  PubMed          Journal:  Radiat Oncol Investig        ISSN: 1065-7541


  2 in total

1.  Oral administration of melatonin modulates the expression of tumor necrosis factor-α (TNF-α) gene in irradiated rat cervical spinal cord.

Authors:  Gholam Hassan Haddadi; Reza Fardid
Journal:  Rep Pract Oncol Radiother       Date:  2015-02-21

2.  Radioprotective effect of melatonin on the cervical spinal cord in irradiated rats.

Authors:  Gholamhassan Haddadi; Alireza Shirazi; Zargham Sepehrizadeh; Seied Rabie Mahdavi; Maryam Haddadi
Journal:  Cell J       Date:  2013-02-20       Impact factor: 2.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.